Drug name - Orilissa
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7419983 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2024
(1 year, 9 months from now) | |
| US7056927 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(1 year, 11 months from now) | |
| CN100424078C | ABBVIE INC | As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives |
Jul, 2024
(1 year, 9 months from now) | |
| CN1819829A | ABBVIE INC | As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives |
Jul, 2024
(1 year, 9 months from now) | |
| IN200600072P1 | ABBVIE INC | Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists |
Jul, 2024
(1 year, 9 months from now) | |
| IN312234B | ABBVIE INC | Pyrimidine-2, 4-Dione Based Compounds As Gonadotropin-Releasing Hormone Receptor Antagonists |
Jul, 2024
(1 year, 9 months from now) | |
| EP1646389A1 | ABBVIE INC | Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists |
Jul, 2024
(1 year, 9 months from now) | |
| EP1646389B1 | ABBVIE INC | Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists |
Jul, 2024
(1 year, 9 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7176211 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jul, 2024
(1 year, 9 months from now) | |
| US10537572 | ABBVIE INC | Methods of administering elagolix |
Sep, 2036
(13 years from now) | |
| US10682351 | ABBVIE INC | Methods of administering elagolix |
Sep, 2036
(13 years from now) | |
Drugs and Companies using ELAGOLIX SODIUM ingredient
Treatment: Management of moderate to severe pain associated with endometriosis; Management of moderate to severe pain associated with endometriosis using 150mg elagolix while co-administering rifampin; Management of moderate to severe pain associated with endometriosis using 150 mg elagolix while co-administering ketoconazole
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 150MG BASE | TABLET;ORAL | Prescription |
| EQ 200MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.